Novartis Venture Fund returned for the small molecule drug developer’s series B round, tipping its total funding to over $100m.

The immuno-oncology drug developer’s prospective initial public offering would mark exits for Takeda, Merck Group, Ipsen and Merck & Co.

The diversified therapeutics developer has filed to go public in the United States a year after Pfizer contributed to its $310m series A round.

UChicago spinout Pyxis Oncology is aiming to raise more than $153m in its initial public offering, having set a price range of $14 to $16.

Sesame Ventures helped lazy eye treatment developer Luminopia raise $12m while UPS, Qualcomm and Mercado Libre exited courier marketplace Mandaê in a purchase by Nuvemshop.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

SoftBank invested $125m through a $160m private placement as portfolio company and cancer drug developer Exscientia went public in an offering sized at nearly $305m.

The Fosun-backed ophthalmology equipment provider raised cash that will go to research, recruitment and commercialisation activities.

Boehringer Ingelheim Venture Fund and Pierre Fabre have made capital commitments to Advent France Biotechnology’s second fund.

The Sony-backed surgical robotics developer has raised $87m in total having received series B funding from investors including Nvidia.